Opicapone odds ratio in relative OFF-time reduction: a post-hoc analysis from combined BIPARK-I and II data
Objective: To evaluate the opicapone (OPC) associated patient’s odds ratio (OR) in relative OFF-time reduction. Background: OPC, a once-daily COMT inhibitor, proved effective in the…Apigenin loaded Phospholipid based nanoemulsion in Therapeutics of Parkinson’s Disease Via Attenuation of Oxidative Stress and Upregulation of Dopamine.
Objective: The aim of the present study was to develop, optimizes and evaluate the antiparkinson effects of apigenin loaded phospholipid based nanoemulsion via attenuation of…Incidence of treatment-emergent adverse events in Parkinson’s disease patients according to baseline MAO-B inhibitors use: post-hoc analysis from double-blind combined BIPARK-I and II data
Objective: To evaluate the incidence of treatment-emergent adverse events (TEAEs) in levodopa-treated Parkinson’s Disease (PD) patients with motor fluctuations and taking opicapone (OPC). Background: OPC…A Phase 2 Study of the Efficacy, Durability and Safety of Ampreloxetine (TD-9855), a Norepinephrine Reuptake Inhibitor, Given Once-daily to Treat Neurogenic Orthostatic Hypotension (nOH) in Subjects with Synucleinopathies
Objective: To assess the efficacy and durability using validated symptom questionnaire OHQ, and safety of ampreloxetine, given once-daily to treat neurogenic orthostatic hypotension (nOH) in…Influence of demographic characteristics in the efficacy response of Parkinson’s disease patients with motor fluctuations: post-hoc analysis from combined BIPARK-I and II.
Objective: To evaluate the impact of demographic characteristics in the efficacy response of levodopa-treated Parkinson’s Disease (PD) patients with motor fluctuations. Background: Opicapone (OPC), a…African American patients with Parkinson’s disease: A hospital-based study compared to Caucasian patients
Objective: To characterize the demographic, socioeconomic, clinical and healthcare features of African American (AA) patients with Parkinson’s disease (PD) compared to Caucasian PD patients in…Incidence of treatment-emergent adverse events in Parkinson’s disease patients according to baseline disease severity: post-hoc analysis from double-blind combined BIPARK-I and II data
Objective: To evaluate the incidence of treatment-emergent adverse events (TEAEs) in levodopa-treated Parkinson’s Disease (PD) patients with motor fluctuations and taking opicapone (OPC). Background: OPC…A Phase 2 Dose Escalation Study of Ampreloxetine (TD-9855), a Norepinephrine Reuptake Inhibitor, Given Once-Daily to Treat Neurogenic Orthostatic Hypotension (nOH) in Subjects with Synucleinopathies
Objective: To assess the acute effects of ampreloxetine on the pressor response, improvement of symptoms and safety in a daily, single, escalating doses. Background: nOH…Influence of motor fluctuations duration, levodopa dose and duration of use in efficacy responses of Parkinson’s disease patients: post-hoc analysis from combined BIPARK-I and II.
Objective: To evaluate the impact of motor fluctuations (MF) duration, levodopa dose and levodopa duration of use (LDU) in efficacy responses of levodopa-treated Parkinson’s Disease…Influence of controlled-release levodopa on quality of sleep and nocturnal movements
Objective: To evaluate the effects of controlled-released (CR) levodopa on quality of sleep and nocturnal movements as assessed with mobile health technology in patients with…
- « Previous Page
- 1
- …
- 23
- 24
- 25
- 26
- 27
- …
- 36
- Next Page »